Biomarkers and clinical outcomes after tezepelumab cessation: extended follow-up from the 2-year DESTINATION study

Long-term tezepelumab treatment in the DESTINATION study (NCT03706079) resulted in reduced asthma exacerbations, reduced biomarker levels and improved lung function and symptom control in patients with severe, uncontrolled asthma.

Source: Annals of Allergy, Asthma and Immunology - April 29, 2024 Category: Allergy & Immunology Authors: Christopher E. Brightling, Marco Caminati, Jean-Pierre Llanos, Scott Caveney, Ales Kotalik, Janet M. Griffiths, Anna Lundahl, Elliot Israel, Ian D. Pavord, Michael E. Wechsler, Celeste Porsbjerg, Jonathan Corren, Monika Go łąbek, Neil Martin, Sandhia Po Source Type: research